Sigilon Therapeutics announced today that Chief Executive Officer Rogerio Vivaldi will present at a number of upcoming high-profile investor and health care conferences.
Sigilon Therapeutics announced the expansion of its patent portfolio with a newly granted U.S. patent (Patent No. US 10,172,791 B2) that further builds on the company’s strong intellectual property position.
Sigilon Therapeutics and the Massachusetts Institute of Technology announced a strategic research collaboration leveraging cutting-edge synthetic biology approaches developed by professor Ron Weiss of the MIT Synthetic Biology Center.
Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics, today announced the appointment of four new members of its senior management team as the company prepares to advance its lead therapeutic candidate into clinical trials.
Sigilon Therapeutics, a biopharmaceutical company that discovers and develops shielded living therapeutics, today announced that two members of its executive leadership team will present at the 2018 Cell & Gene Meeting on the Mesa in La Jolla, California.
Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutics, today announced that Rogerio Vivaldi, M.D., has joined the company as Chief Executive Officer. Dr. Vivaldi joins the Sigilon team from Bioverativ, a Sanofi company.
Sigilon's Afibromer technology will be used to encapsulate insulin-producing cells for the potential treatment of type 1 diabetes
Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that its Afibromer™ Living Therapeutic candidate SIG-003 has been granted an Advanced Therapy Medicinal Product (ATMP) designation by the Committee for Advanced Therapies of the European Medicines Agency.
CAMBRIDGE, Mass., March 9, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at Cowen & Company 38th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 8, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conferences.
Elsevier, the global information analytics business specializing in science and health, today announced that six start-up companies have been selected from more than 150 global applicants for The Hive, Elsevier’s innovation initiative for biotech and pharmaceutical start-ups......Sigilon Therapeutics.
Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on development of therapeutics for metabolic disorders and in the identification and evaluation of emerging technologies.
Sigilon Therapeutics will present at the following conferences in January: Biotech Showcase 2018 and Cell & Gene Therapy World 2018.
Sigilon Therapeutics, today announced that it will host a live, online educational webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Monday, Dec. 4, 2017, at 10 a.m. EST. Following presentations by Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Sigilon scientific advisory board, journalist Luke Timmerman will moderate a discussion of questions submitted by audience participants on current methods and promising new protein delivery technologies.
Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations, will present at the upcoming 2017 Biotech and Money Inv€$tival Showcase, organized in partnership with Jefferies LLC, and attend the Jefferies 2017 London Healthcare Conference taking place Nov. 15-16, 2017
“Mr. Shaff’s experience in company building, finance, and corporate development, notably in emerging areas of biotechnology, will be particularly helpful as we develop a new Afibromer™ cell factory approach to the treatment of chronic diseases,” said Douglas Cole, M.D., Chairman of the Board of Sigilon Therapeutics.
Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that James Watson, Chief Business Officer, will present at the BIO Investor Forum to be held Oct. 17-18, 2017
Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the formation of a scientific advisory board (SAB) to guide the development of therapeutics based on proprietary engineered cell lines and Afibromer™ biomaterials technology.
Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations to present at the Cell and Gene Meeting on the Mesa on October 5th in La Jolla, California.
CAMBRIDGE, Mass., Sept. 7, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the company will present at the following conferences in September.
Follow our mission at Sigilon Therapeutics by opting in for important news and events.
One of the biggest milestones we anticipate for 2019 is the start of clinical trials for our lead candidate, SIG-001, in hemophilia A.
Cambridge, Mass., biotech startup working to unlock new applications for cell therapies — particularly for type 1 diabetes — is getting new leadership.
It will be Vivaldi’s job now to get the startup in the clinic, looking to move the pipeline beyond its initial forays into diabetes, hemophilia and lysosomal storage disorders.
A little more than one year after Flagship Pioneering launched Sigilon Therapeutics, the company has a new chief executive officer.
Sigilon Therapeutics is bringing on Bioverativ’s chief global therapeutic operations officer, Rogerio Vivaldi, M.D., to serve as its CEO.
US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader.
“There are two elements that I’m familiar with which relate to Sigilon in particular. We have a technology that hides implants from the immune system so that the immune system won’t attack those implants. That means for the first time now we can manufacture cellular implants so you can do things like the artificial pancreas, which is what we did with Eli Lilly & Co.. Or you can manufacture implants that become cell factories, which can do things like treat hemophilia by manufacturing Factor VIII or Factor IX.”
In April, insulin maker Eli Lilly announced it would invest up to $473 million in Sigilon Therapeutics and the cell encapsulation technology the Cambridge, Mass., biotech company is developing was big news in the type 1 diabetes space. We’ve been following this encapsulation technology since I met with Arturo Vegas in 2015, when he was a chemistry post doc at MIT working Robert Langer and Daniel Anderson at the Koch Institute for Integrative Cancer Research.
Paul Wotton, Ph.D., CEO of Sigilon Therapeutics, discusses his company’s approach for delivering cells that avoid immune detection.
Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells…
In patients who suffer from Type I diabetes, pancreatic beta cells are killed off by the immune system. Lilly and Sigilon plan to encapsulate induced pluripotent stem cells that are engineered into insulin-producing pancreatic beta cells. Ultimately, the companies hope, these products can restore a person’s insulin production without alarming their immune system.
Sigilon Therapeutics Inc. (Cambridge, Mass.) granted Eli Lilly and Co. (NYSE:LLY) exclusive, worldwide rights to Sigilon’sType I diabetes program in a deal potentially worth over $470 million.
The startup is developing what it calls “living therapeutics” — drugs based on engineered cells that can fight a range of disorders when implanted in the body.
Today Sigilon is announcing a $473 million pact with Eli Lilly — which is stepping out under a bolder R&D chief in Dan Skovronsky — to drive their stem cell work on Type 1 diabetes into the clinic, with $63 million of that in an upfront and the rest divvied up with a goal of fully funding the development of a durable new therapy for the disease.
Medgadget editor Tom Peach recently spoke with Devyn Smith PhD, Chief Strategy Officer of Sigilon Therapeutics, to learn more about the company’s technology.
“Biotechs are surrounded by innovation; they make science fiction—a digital pill, 3D printing, wearable technology—a reality; are located in trendy tech hubs like San Francisco, San Diego, and Boston; and most importantly, they offer hope.”
A few months ago, Flagship unveiled Sigilon Therapeutics, a Cambridge startup that is aiming to develop a new class of “living therapeutics”
Four early-stage venture-funded biotechnology companies have signed leases at 100 Binney St. in Cambridge.
Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionary biocompatible Afibromer™ technology, a new class of implantable biomaterials that do not trigger fibrosis.
Sigilon’s allogeneic cell therapy implants offer long-term but flexible dosing
Venture investors are betting that cell therapies will bring about better treatments or even cures for a widening range of diseases.
Follow our mission at Sigilon Therapeutics by opting in for important news and events.
We are proud to be invited to speak at conferences about our technology. Below are some of the conferences where you can see and learn more about us:
Follow our mission at Sigilon Therapeutics by opting in for important news and events.
Peer-reviewed publications describing Sigilon Therapeutics’s research include:
Cell and gene therapies hold the promise of providing significant and durable health gains to patients in many disease states and have recently elicited significant investor and partner interest. We cover the current state of industry partnerships and investments, highlight what makes a partnership advantageous, and discuss implications for stem cell therapies.
Afibromer™ protein factories represent a flexible and programmable alternative to gene therapies.
When encapsulated with alginate derivatives that resist the foreign-body response, human embryonic stem cell–derived beta cells restore long-term normoglycemia in immunocompetent mice without the need for immunosuppression.
Implanted spheres of a broad variety of material classes significantly abrogate foreign body reactions and fibrosis in rodent and non-human primates when the spheres are larger than 1.5 mm in diameter.
In vivo screening of a large combinatorial library of alginates identifies materials that elicit a substantially reduced foreign body response.
Host recognition and immune-mediated foreign body response to biomaterials can compromise the performance of implanted medical devices.
Follow our mission at Sigilon Therapeutics by opting in for important news and events.
A 
Company
